What Is Sermorelin? GHRH Research Peptide Guide (2026)
The growth hormone axis has a regulatory architecture that most researchers working with GH secretagogues encounter early but rarely examine in full detail. Growth hormone is not simply secreted on demand — its release is coordinated by two opposing hypothalamic signals that pulse in alternation: growth hormone-releasing hormone (GHRH), which drives GH release, and somatostatin, which suppresses it. The interplay between these two signals produces the characteristic pulsatile pattern of GH secretion that is a fundamental feature of normal GH axis physiology.
Sermorelin was built to activate one side of that system as precisely as possible. It is the shortest synthetic GHRH fragment that retains full biological activity at the GHRH receptor, giving researchers a tool for studying GH axis stimulation that operates through the physiological pulsatile mechanism rather than bypassing it. Understanding what Sermorelin is, where it came from, and what distinguishes it from the other GHRH analogs in the research peptide landscape is what this guide covers.
What Sermorelin Is
Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29 NH2). Its molecular weight is approximately 3,357.93 Da and its CAS number is 86168-78-7. It is also called GRF (1-29) — growth hormone-releasing factor, positions 1 through 29 — reflecting the nomenclature that predates the more commonly used GHRH designation.
The significance of the 1-29 fragment is pharmacological precision: published research has established that the first 29 amino acids of the 44-amino acid endogenous GHRH molecule constitute the biologically active domain necessary and sufficient for GHRH receptor binding and GH release. Residues 30 through 44 of native GHRH contribute to structural stability but are not required for receptor activation. Sermorelin’s truncation at position 29 retains full receptor binding affinity while producing a shorter and more practical research compound than the full 44-amino acid native sequence.
Sermorelin carries something that most research peptides do not: a documented regulatory history including FDA approval. Sermorelin acetate was approved by the FDA in 1990 under the brand name Geref for the diagnosis of growth hormone deficiency, with subsequent approval for treatment of idiopathic GH deficiency in children. The original commercial product was voluntarily withdrawn in 2008 by EMD Serono for commercial rather than safety reasons — the diagnostic testing market was small and alternative diagnostics had become dominant. The compound’s FDA history provides a clinical reference base that distinguishes it from all other GHRH analogs currently in the research peptide catalog.
In February 2026, Sermorelin was among the peptides moved from FDA Category 2 back to Category 1 as part of HHS Secretary Kennedy’s announcement restoring compounding access to several peptides — allowing licensed compounding pharmacies to prepare it again with a physician’s prescription. This reclassification does not constitute FDA drug approval. For laboratory research, Sermorelin is available under the research use only framework independently of these compounding regulations.
Compound specifications:
| Property | Detail |
|---|---|
| Full name | Sermorelin acetate |
| Also known as | GHRH(1-29)NH2, GRF(1-29) |
| CAS number | 86168-78-7 |
| Amino acids | 29 |
| Molecular weight | ~3,357.93 Da |
| Receptor target | GHRH receptor (GHRHR) on pituitary somatotrophs |
| Intracellular signaling | Gs-coupled — adenylyl cyclase — cAMP — PKA |
| GH release pattern | Pulsatile — physiological |
| Half-life | ~10 to 20 minutes |
| DPP-IV cleavage | Yes — at Tyr-Ala bond positions 1-2 |
| FDA approval history | Approved 1990 as Geref — withdrawn 2008 |
| 2026 regulatory status | Category 1 — compounding access restored Feb 2026 |
| Supplied form | Lyophilized powder |
| Vial size | 2mg |
| Storage lyophilized | -20°C up to 24 months |
| Storage reconstituted | 2 to 8°C up to 28 days |
The GHRH System — What Sermorelin Is Activating
To understand Sermorelin’s research utility, the GHRH receptor system it activates deserves precise description.
GHRH — growth hormone-releasing hormone — is produced by neurons in the arcuate nucleus of the hypothalamus and secreted into the hypothalamic-pituitary portal circulation in discrete pulses. These pulses reach the anterior pituitary, where they bind to GHRH receptors (GHRHR) on somatotroph cells — the specialized pituitary cells whose primary function is synthesizing and secreting growth hormone. GHRH receptor binding triggers Gs protein coupling, adenylyl cyclase activation, and elevation of intracellular cyclic AMP (cAMP). The elevated cAMP activates protein kinase A (PKA), which phosphorylates transcription factors that drive GH gene transcription, promotes GH synthesis, and stimulates the calcium-dependent fusion of GH-containing secretory vesicles with the somatotroph cell membrane — releasing GH into the portal and then systemic circulation.
The somatostatin counterpart of this system — released from the periventricular nucleus of the hypothalamus — inhibits GH secretion by activating Gi-coupled somatostatin receptors on somatotrophs, reducing cAMP and preventing vesicle fusion. The alternating pulses of GHRH stimulation and somatostatin inhibition produce the characteristic pulsatile GH secretion pattern: GH peaks during GHRH pulses and falls to baseline during somatostatin surges.
What makes Sermorelin a uniquely useful research tool within this system is that it activates GHRHR through exactly the same mechanism as endogenous GHRH — Gs coupling, cAMP elevation, PKA activation — without the additional receptor interactions that characterize GHS-R1a agonists like Ipamorelin or GHRP-6. This receptor selectivity means that Sermorelin’s effects can be attributed specifically to GHRHR activation rather than confounded by GHS-R1a-mediated effects on cortisol, appetite, or the calcium mobilization cascade that GHS-R1a agonists trigger.
Sermorelin also preserves the somatostatin feedback loop. Because it activates GHRHR rather than directly releasing GH from storage vesicles, somatostatin can still exert its inhibitory regulation on the GH release response — producing GH pulses whose amplitude is modulated by the existing somatostatin tone in the system. This preserved feedback regulation is what gives Sermorelin its physiological GH pulse pattern and makes it the appropriate research tool for protocols where preserving the natural feedback architecture of the GH axis is scientifically important.
Mechanism of Action — The Molecular Detail
Sermorelin’s receptor pharmacology has been characterized in substantial detail across the published literature because of its FDA approval history and the clinical research programs that accompanied it.
GHRH receptor binding and Gs signaling: Sermorelin binds GHRHR with full agonist activity — the 1-29 fragment retains equivalent receptor binding affinity to the full 44-amino acid GHRH sequence at the same receptor, as established by the foundational work of Lance et al. in 1984. Receptor binding activates Gs protein coupling, stimulating adenylyl cyclase and elevating intracellular cAMP concentrations in somatotroph cells.
cAMP-PKA cascade: Elevated cAMP activates protein kinase A, which phosphorylates the transcription factor CREB (cAMP response element binding protein). Phosphorylated CREB drives transcription of the GH gene (GH1), increasing GH mRNA and GH protein synthesis in somatotrophs. PKA also phosphorylates voltage-gated calcium channels and other components of the vesicle secretion machinery, promoting calcium influx and GH secretory vesicle exocytosis.
Pulsatile GH release: The GH release Sermorelin produces is pulsatile rather than sustained — it rises sharply following administration as the GHRHR activation drives somatotroph secretion, peaks within 15 to 30 minutes in research models, and returns toward baseline as Sermorelin is cleared from the circulation and somatostatin reasserts its inhibitory regulation. This pulsatile kinetic profile is the defining pharmacodynamic characteristic that distinguishes Sermorelin from CJC-1295 with DAC, which produces sustained GH elevation over days by preventing the rapid clearance that terminates Sermorelin’s receptor engagement.
DPP-IV susceptibility: Sermorelin is rapidly cleaved by dipeptidyl peptidase IV (DPP-IV) at the Tyr-Ala bond between positions 1 and 2 of the peptide sequence. This enzymatic cleavage — which removes the first two amino acids and inactivates the N-terminal receptor-binding domain — is responsible for Sermorelin’s short plasma half-life of approximately 10 to 20 minutes. CJC-1295 was subsequently developed specifically to address this vulnerability through an alanine-to-Aib substitution at position 2 that blocks DPP-IV access — making the comparison between Sermorelin and CJC-1295 one of the clearest pharmacokinetic research designs available in the GHRH analog literature.
The GHRH Analog Family — Where Sermorelin Sits
Sermorelin is the oldest and most clinically characterized member of the GHRH analog research family, which now includes Sermorelin, CJC-1295 (with and without DAC), and Tesamorelin. Understanding how they relate clarifies when each is the appropriate research tool.
Sermorelin is GHRH(1-29) with no modifications. Full DPP-IV susceptibility at position 1-2. Half-life 10 to 20 minutes. Pulsatile GH release. Strongest clinical evidence base. Most physiologically faithful GHRH receptor activation pattern.
CJC-1295 without DAC (Mod GRF 1-29) incorporates an alanine-to-Aib substitution at position 2 and several other modifications that block DPP-IV cleavage sites throughout the sequence. Half-life approximately 30 minutes. Predominantly pulsatile with extended receptor engagement.
CJC-1295 with DAC adds an albumin-binding Drug Affinity Complex moiety that extends the half-life to 6 to 8 days through reversible covalent binding to serum albumin. Sustained continuous GH axis activation rather than pulsatile.
Tesamorelin is a modified full-length GHRH(1-44) analog with a trans-3-hexenoic acid modification at the N-terminus that improves DPP-IV resistance. FDA-approved as Egrifta for HIV-associated lipodystrophy. Half-life approximately 26 minutes. The only GHRH analog with full Phase 3 clinical trial data for metabolic endpoints.
| Compound | Sequence | DPP-IV | Half-life | GH Pattern | Clinical Data |
|---|---|---|---|---|---|
| Sermorelin | GHRH(1-29) | Susceptible | 10-20 min | Pulsatile | Extensive — FDA approved |
| CJC-1295 no DAC | GHRH(1-29) + Aib2 | Resistant | ~30 min | Pulsatile | Limited |
| CJC-1295 DAC | GHRH(1-29) + Aib2 + DAC | Resistant | 6-8 days | Sustained | Limited |
| Tesamorelin | GHRH(1-44) modified | Resistant | ~26 min | Pulsatile | Phase 3 — FDA approved |
For a detailed comparison of Sermorelin and CJC-1295 across mechanism, pharmacokinetics, and research applications, see our Sermorelin vs CJC-1295 research guide.
Research Applications
Sermorelin is examined in laboratory settings across several interconnected GH axis research domains.
GHRH receptor pharmacology research uses Sermorelin as the reference compound for characterizing GHRHR activation — its FDA approval history means it carries the most complete published pharmacology data of any GHRH analog, including receptor binding kinetics, downstream cAMP dynamics, and GH secretory response characterization across multiple experimental systems.
GH pulsatility research uses Sermorelin specifically because its rapid clearance and DPP-IV susceptibility reproduce the pharmacokinetics of endogenous GHRH — making it the appropriate tool for research questions about how pulsatile GH secretion dynamics affect downstream biology, somatotroph recovery kinetics between pulses, and receptor resensitization after stimulation.
Somatopause research uses Sermorelin to study age-related GH decline — the progressive reduction in GH pulse amplitude and IGF-1 levels that characterizes biological aging. Published research has documented that Sermorelin administration in aged experimental models partially restores GH pulsatility where pituitary somatotroph GHRH receptor sensitivity remains intact — a finding consistent with the hypothesis that somatopause reflects declining hypothalamic GHRH output rather than intrinsic somatotroph failure.
DPP-IV cleavage research uses Sermorelin and its DPP-IV-resistant analogs as paired research tools to study the specific contribution of DPP-IV cleavage to GHRH analog pharmacokinetics. The contrast between Sermorelin’s 10 to 20-minute half-life and CJC-1295’s extended half-life provides one of the cleanest experimental designs for isolating DPP-IV’s role in GH axis regulation — same receptor, same intracellular cascade, different temporal profiles.
Sleep architecture research examines Sermorelin’s documented effects on slow-wave sleep duration — a well-characterized relationship between GHRHR activation and sleep quality that reflects the bidirectional relationship between GH secretion and sleep architecture. GH is primarily secreted during slow-wave sleep, and GHRH administration both promotes GH release and increases slow-wave sleep duration through mechanisms that overlap with the brain’s endogenous sleep regulatory systems.
Combined GHRH and GHS-R1a research uses Sermorelin alongside Ipamorelin in dual-pathway GH release protocols, examining how GHRHR activation and GHS-R1a activation converge synergistically on somatotroph GH output through different intracellular mechanisms — cAMP for the GHRHR pathway, calcium mobilization for the GHS-R1a pathway.
Sermorelin and the Ipamorelin Research Combination
The Sermorelin and Ipamorelin combination is the most commonly studied dual-pathway GH axis protocol in the research peptide literature, and the mechanistic rationale for combining them is grounded in the complementary nature of their receptor pharmacology.
Sermorelin activates GHRHR through Gs-mediated cAMP elevation — a pathway that increases GH synthesis, primes somatotrophs for secretion, and suppresses somatostatin release from the hypothalamus. Ipamorelin activates GHS-R1a through Gq/11-mediated phospholipase C activation and calcium mobilization — a pathway that directly drives secretory vesicle exocytosis.
The two pathways converge on somatotroph GH release through different intracellular routes. When both are activated simultaneously, the cAMP signal from Sermorelin enhances the somatotroph’s readiness for secretion while the calcium signal from Ipamorelin directly triggers that secretion — producing a GH output that substantially exceeds what either compound achieves alone. This synergistic relationship, documented across multiple research models, makes the Sermorelin plus Ipamorelin combination a standard protocol for studying maximal physiological GH axis stimulation.
The Ipamorelin component contributes an additional advantage: as a highly selective GHS-R1a agonist, it produces no significant cortisol, ACTH, or prolactin elevation — limiting the combination protocol’s off-target hormonal effects to the GHRHR-mediated somatostatin suppression that Sermorelin produces, which is a physiologically expected consequence of GHRHR activation rather than an off-target effect. For more on Ipamorelin’s research profile see our What Is Ipamorelin guide.
Quality Standards for GHRH Research
GH axis research using Sermorelin requires compound quality documentation for the same reasons all receptor pharmacology research does: the dose-response relationship being characterized is only valid if the compound concentration used accurately reflects the intended dose. HPLC purity analysis confirming at least 99% compound purity is the baseline standard.
Mass spectrometry identity confirmation is specifically important for Sermorelin because DPP-IV cleavage during storage or preparation — removing the first two amino acids — can produce a truncated compound that tests at acceptable HPLC purity while being biologically inactive at GHRHR. Mass spectrometry verifying the full molecular weight of intact GHRH(1-29) distinguishes active from DPP-IV-cleaved material in ways that HPLC alone cannot.
Endotoxin screening matters in GH axis research because endotoxin produces hypothalamic-pituitary-adrenal axis activation that directly alters GH secretion patterns — contaminated Sermorelin in an in vivo GH pulse study would produce confounded results attributable to endotoxin-driven stress rather than GHRHR pharmacology. Sterility testing confirms the absence of microbial contamination.
All Patriot Peptides Sermorelin (2mg) is manufactured in a cGMP-certified US facility and independently tested by a certified third-party laboratory across all four criteria. Batch-specific Certificates of Analysis are available for all products. For laboratory research use only.
Storage and Handling
Sermorelin (2mg) is supplied as lyophilized powder in a sterile glass vial. Store lyophilized vials at -20°C, protected from light and moisture, for up to 24 months. Allow sealed vials to equilibrate to room temperature before opening — approximately 15 to 20 minutes — to prevent moisture condensation inside the vial. Reconstitute with bacteriostatic water by running the solvent slowly down the inside wall of the vial and allow 5 to 10 minutes of passive dissolution without agitation. Do not shake or vortex. A properly reconstituted Sermorelin solution should be completely clear and colorless. Once reconstituted, refrigerate at 2 to 8°C and use within 28 days. Do not freeze reconstituted solutions. For complete reconstitution and storage guidance see our How to Store Lyophilized Peptides guide.
Frequently Asked Questions
What is Sermorelin? Sermorelin is a synthetic 29-amino acid peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29 NH2). It is the shortest GHRH fragment that retains full biological activity at the GHRH receptor, producing pulsatile GH release from pituitary somatotrophs through the same Gs-cAMP-PKA mechanism as endogenous GHRH. It was FDA-approved in 1990 as Geref for GH deficiency diagnosis. For laboratory research use only.
How does Sermorelin work? Sermorelin binds the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating Gs protein coupling and adenylyl cyclase. Elevated intracellular cAMP activates protein kinase A, which drives GH gene transcription, GH synthesis, and calcium-dependent GH secretory vesicle exocytosis. The resulting GH release is pulsatile, peaking 15 to 30 minutes post-administration in research models and returning to baseline as Sermorelin is cleared and somatostatin reasserts inhibitory regulation.
What is the difference between Sermorelin and CJC-1295? Both activate GHRHR through the same Gs-cAMP mechanism. Sermorelin has an alanine at position 2 that makes it susceptible to DPP-IV cleavage, producing a half-life of 10 to 20 minutes and pulsatile GH release. CJC-1295 substitutes Aib at position 2 to block DPP-IV cleavage, extending the half-life to approximately 30 minutes without DAC and to 6 to 8 days with DAC. The pharmacokinetic difference is the primary experimental variable that makes the two compounds useful for different research questions. For full details see our Sermorelin vs CJC-1295 research comparison.
Why is Sermorelin combined with Ipamorelin in research protocols? Sermorelin activates GHRHR through a cAMP-dependent pathway. Ipamorelin activates GHS-R1a through a calcium-dependent pathway. The two mechanisms converge on somatotroph GH release through different intracellular routes, producing synergistic GH output that substantially exceeds what either compound achieves alone — a dual-pathway approach that is standard for GH axis research requiring maximal physiological GH stimulation.
Was Sermorelin FDA approved? Yes. Sermorelin acetate (Geref) was FDA-approved in 1990 for GH deficiency diagnosis and subsequently for treatment of idiopathic GH deficiency in children. The product was voluntarily withdrawn in 2008 for commercial rather than safety reasons. In February 2026, Sermorelin was restored to Category 1 on the FDA bulk drug substances list, allowing licensed compounding pharmacies to prepare it with a physician’s prescription. It remains available for laboratory research under the research use only framework.
Where can I buy research-grade Sermorelin? Patriot Peptides Sermorelin (2mg) is manufactured in a cGMP-certified US facility and independently third-party tested for HPLC purity, mass spectrometry identity, endotoxin, and sterility. Batch-specific Certificates of Analysis are available. For laboratory research use only.
All content is for informational and educational purposes only. All Patriot Peptides products are strictly for laboratory research use only. Not for human consumption, veterinary use, or clinical application.
Related reading: Sermorelin vs CJC-1295: Key Research Differences | What Is Ipamorelin? | CJC-1295 vs Ipamorelin | How to Store Lyophilized Peptides